KYMR
Kymera Therapeutics Inc
NASDAQ: KYMR · HEALTHCARE · BIOTECHNOLOGY
$81.51
-2.79% today
Updated 2026-04-29
Market cap
$6.65B
P/E ratio
—
P/S ratio
169.71x
EPS (TTM)
$-3.69
Dividend yield
—
52W range
$28 – $103
Volume
0.7M
Kymera Therapeutics Inc (KYMR) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $44.23M | $116.70M | $487.18M | $605.90M | $603.13M | $575.76M | $978.03M |
| Cash & equivalents | $41.26M | $76.02M | $31.00M | $47.98M | $68.39M | $109.97M | $120.26M |
| Current assets | $41.79M | $92.84M | $302.34M | $451.27M | $419.42M | $405.32M | $510.27M |
| Total liabilities | $78.67M | $191.11M | $203.29M | $146.27M | $112.98M | $180.79M | $142.42M |
| Current liabilities | $4.69M | $34.57M | $110.62M | $92.54M | $71.34M | $85.69M | $67.77M |
| Long-term debt | — | — | — | — | — | — | — |
| Shareholder equity | $-34.44M | $-74.41M | $283.89M | $459.64M | $490.15M | $394.97M | $835.62M |
| Retained earnings | $-35.21M | $-76.46M | $-128.76M | $-228.98M | $-383.79M | $-530.75M | $-754.61M |
| Accounts receivable | $148000.00 | $287000.00 | $1.43M | $135000.00 | $2.54M | $18.76M | $947000.00 |
| Inventory | — | — | $-163.39M | $-8.99M | $-12.25M | $1.00 | — |
| Goodwill | — | — | — | — | — | — | — |